The impact of interval from surgery to chemotherapy and age in advanced-stage ovarian cancer: A GOG ancillary study.

被引：0
|
作者：
Menzin, Andrew
Java, James
Lovecchio, John L.
Chi, Dennis
Tew, William P.
Bookman, Michael A.
Lichtman, Stuart M.
机构：
[1] N Shore Univ Hosp, Manhasset, NY USA
[2] New York State Dept Hlth, Roswell Pk Mem Inst, Gynecol Oncol Grp, Buffalo, NY 14263 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Arizona Canc Ctr, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5057
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Chemotherapy followed by interval cytoreductive surgery: The most prevalent approach in the upfront treatment of patients with advanced-stage epithelial ovarian cancer in the United States
    Bercow, Alexandra
    Stewart, Taylor
    Bregar, Amy
    Gockley, Allison
    Mazina, Varvara
    Rauh-Hain, J. Alejandro
    Melamed, Alexander
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S347 - S347
  • [42] The role of cytoreductive surgery in advanced-stage ovarian cancer: A systematic review
    Vitale S.G.
    Marilli I.
    Lodato M.
    Tropea A.
    Cianci A.
    Updates in Surgery, 2013, 65 (4) : 265 - 270
  • [43] Subtotal Colectomy as Part of Debulking Surgery for Advanced-stage Ovarian Cancer
    Bacalbasa, Nicolae
    Diaconu, Camelia
    Iliescu, Laura
    Dima, Simona
    Bratu, Ovidiu Gabriel
    Cretoiu, Dragos
    Neacsu, Adrian
    Filipescu, Alexandru
    Savu, Cornel
    Balescu, Irina
    IN VIVO, 2020, 34 (05): : 2757 - 2761
  • [44] POSITIVE PERITONEAL CYTOLOGY AT THE TIME OF INTERVAL DEBULKING SURGERY IS HIGHLY PREDICTIVE OF PROGNOSIS IN ADVANCED-STAGE OVARIAN CANCER
    Kato, K.
    Omatsu, K.
    Usami, T.
    Taniguchi, T.
    Yamamoto, A.
    Ushioda, N.
    Nomura, H.
    Matoda, M.
    Okamoto, S.
    Kondo, E.
    Umayahara, K.
    Takeshima, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 66 - 66
  • [45] Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Narod, Steven
    Sopik, Victoria
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 238 - 240
  • [46] Chemotherapy dose reduction is associated with poor survival in advanced-stage ovarian cancer
    Chura, J. C.
    Axtell, A.
    Pavelka, J.
    Boyd, A.
    Downs, L. S.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S12 - S13
  • [47] Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer
    Kim, Se Ik
    Kim, Hee Seung
    Kim, Tae Hun
    Suh, Dong Hoon
    Kim, Kidong
    No, Jae Hong
    Chung, Hyun Hoon
    Kim, Yong Beom
    Song, Yong Sang
    JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014
  • [48] IMPACT OF INTERVAL FROM DEFINITIVE SURGERY TO INITIATION OF ADJUVANT CHEMOTHERAPY (ISC) ON SURVIVAL FOR ADVANCED EPITHELIAL OVARIAN CANCER
    Heo, E. J.
    Paik, E. S.
    Choi, H. J.
    Yoon, E. R.
    Lee, Y. Y.
    Kim, T. J.
    Lee, J. W.
    Kim, B. G.
    Bae, D. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 454 - 456
  • [49] Timing of chemotherapy does not impact survival in advanced-stage endometrial cancer
    Alter, Raanan
    Kim, Josephine
    Kuchta, Kristine
    Vogel, Tilley Jenkins
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S309 - S310
  • [50] The impact of chemotherapy on quality of life in advanced-stage lung cancer patients
    Fernandes, Sharon S.
    Saini, J. K.
    INDIAN JOURNAL OF CANCER, 2023, 60 (03) : 310 - 315
12345